

Curriculum vitae
MONICA BASSO

Residenza: Via Dei Muretti 23/29, 16035 Rapallo (Ge)

Posizione attuale

Professoressa Associata di Malattie Infettive (SSD MED/17), Dipartimento di Medicina Molecolare, Università degli Studi di Padova –dal 01/11/2022.

Convenzionata come Dirigente Medico a tempo pieno presso l'Unità Operativa Complessa di Malattie Infettive e Tropicali della Azienda Ospedaliera di Padova dal 01/11/2022.

E mail istituzionali:

monica.basso@unipd.it

monica.basso@aopd.veneto.it

Titoli di studio

Laurea in Medicina e Chirurgia il 7 aprile 1997 presso l'Università degli Studi di Genova con votazione 110/110.

Specializzazione in Allergologia e Immunologia Clinica presso l'Università degli Studi di Genova il 5 novembre 2001 con votazione 50/50.

Dottorato di ricerca in Immunologia Clinica e Sperimentale presso l'Università degli Studi di Genova il 3 febbraio 2012

Carriera

Ricercatore a tempo indeterminato di Malattie Infettive (SSD MED/17), Dipartimento di Medicina Molecolare, Università degli Studi di Padova –dal 31/03/2011 al 31/10/2022

Convenzionata come Dirigente Medico a tempo pieno presso l'Unità Operativa Complessa di Microbiologia e Virologia, Azienda Ospedaliera di Padova dal 01/05/2011 al 31/10/2022.

Incarichi

2014-2016: membro del Consiglio della Scuola di Specializzazione in Malattie Infettive della Università degli Studi di Padova per la coorte 30 giugno 2009 (fino al 31/10/16).

2014-2018: membro del Consiglio della Scuola di Specializzazione in Malattie Infettive, aggregata alla Scuola di Verona, capofila per le coorti arruolate nel 2012-13 e 2013-14.

2016-2020: Componente del Comitato Ordinatore della Scuola di Specializzazione in Malattie Infettive aggregata alla Scuola di Brescia, capofila per le coorti arruolate nel 2014-15 e 2015-16.

2017-2020: Componente del Comitato Ordinatore della Scuola di Specializzazione in Malattie Infettive e Tropicali dell'Università di Padova, nella nuova conformazione autonoma, per la coorte 29 dicembre 2017 e successive coorti.

2020-oggi: membro del Consiglio della Scuola di Specializzazione in Malattie Infettive e Tropicali dell'Università degli Studi di Padova.

20 gennaio 2021-oggi: Vice Direttore della Scuola di Specializzazione in Malattie Infettive e Tropicali dell'Università degli Studi di Padova.

Attività didattica

Dal 16-12-2019 membro della Commissione Didattica del Dipartimento di Medicina Molecolare, Università degli Studi di Padova.

Docente dell'insegnamento di Malattie Infettive nel corso di Corso di Laurea in Medicina e Chirurgia dell'Università degli Studi di Padova (sede Padova) dall'AA 2011-2012 all'AA 2016-2017 e dall'AA 2018/2019 ad oggi.

Docente dell'insegnamento di Malattie Infettive nel Corso di Laurea Medicine and Surgery dell'Università degli Studi di Padova dall'AA 2021/2022 ad oggi.

Docente di Malattie Infettive nella Scuola di Specializzazione in Malattie Infettive e Tropicali dall' AA 2010/2011, 2011/2012 e dal 2016/2017 ad oggi.

Membro del Collegio Docenti del Dottorato in Medicina Molecolare della Università degli Studi di Padova.

Docente di Malattie Infettive in corsi di Laurea triennale e nelle Scuole di Specializzazione della Università degli Studi di Padova.

Coordinatrice di Semestre per il 3° anno, 2° semestre del Corso di Laurea Medicine and Surgery dell'Università degli Studi di Padova per l' AA 2023/24.

Elenco pubblicazioni

1. Setti M, Bignardi D, Ballestrero A, Ferrando F, Musselli C, Bianchi S, **Basso M**, Bosco O, Balleari E, Patrone F, Indiveri F. The induction of distinct cytokine cascades correlates with different effects of granulocyte-colony stimulating factor and granulocyte/macrophage-colony-stimulating factor on the lymphocyte compartment in the course of high-dose chemotherapy for breast cancer. *Cancer Immunol Immunother.* 1999;48:287-96.
2. Filaci G, Cutolo M, **Basso M**, Murdaca G, Derchi L, Gianrossi R, Ropolo F, Zentilin P, Sulli A, Puppo F, Indiveri F. Long-term treatment of patients affected by systemic sclerosis with cyclosporin A. *Rheumatology (Oxford).* 2001;40:1431-2.
3. Torre F, Mattioli F, Campo N, Delfino A, **Basso M**, Pelli N, Martelli A, Picciotto A. Serum lamivudine levels in the presence of a lamivudine-resistant HBV mutant. *Dig Liver Dis.* 2004 ;36:677-81.
4. Sulli A, Burroni A, Tuccio M, Pizzorni C, Craviotto C, Ghio M, **Basso M**, Serio B, Cutolo M. La videocapillaroscopia periungueale nella sclerosi sistemica: parametri diagnostici e di follow-up della malattia e correlazione con il tipo di impegno cutaneo e con gli autoanticorpi specifici [Nailfold videocapillaroscopy in systemic sclerosis: diagnostic and follow-up parameters and correlation with both specific serum autoantibodies and subsets of skin involvement]. *Reumatismo.* 2004;56:36-45.
5. Cutolo M, Pizzorni C, Tuccio M, Burroni A, Craviotto C, **Basso M**, Serio B, Sulli A. Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis. *Rheumatology (Oxford).* 2004;43:719-26.
6. Torre F, Rossol S, Pelli N, **Basso M**, Delfino A, Picciotto A. Kinetics of soluble tumour necrosis factor (TNF)-alpha receptors and cytokines in the early phase of treatment for chronic hepatitis C: comparison between interferon (IFN)-alpha alone, IFN-alpha plus amantadine or plus ribavirin. *Clin Exp Immunol.* 2004;136:507-12.
7. **Basso M**, Ghio M, Filaci G, Setti M, Indiveri F. A case of successful pregnancy in a woman with systemic sclerosis treated with cyclosporin. *Rheumatology (Oxford).* 2004;43:1310-1.
8. Filaci G, Rizzi M, Setti M, Fenoglio D, Fravega M, **Basso M**, Ansaldo G, Ceppa P, Borgonovo G, Murdaca G, Ferrera F, Picciotto A, Fiocca R, Torre G, Indiveri F. Non-antigen-specific CD8(+) T suppressor lymphocytes in diseases characterized by chronic immune responses and inflammation. *Ann N Y Acad Sci.* 2005;1050:115-23.
9. **Basso M**, Torre F, Picciotto A. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. *Cancer.* 2005;103:2654-5; author reply 2655.
10. Pelli N, Torre F, Delfino A, **Basso M**, Picciotto A. Soluble tumor necrosis factor-related ligand (sTRAIL) levels and kinetics during antiviral treatment in chronic hepatitis C. *J Interferon Cytokine Res.* 2006;26:119-23.
11. Filaci G, Fravega M, Setti M, Traverso P, Millo E, Fenoglio D, Negrini S, Ferrera F, Romagnoli A, **Basso M**, Contini P, Rizzi M, Ghio M, Benatti U, Damonte G, Ravetti JL, Carmignani G, Zanetti M, Indiveri F. Frequency of telomerase-specific CD8+ T lymphocytes in patients with cancer. *Blood.* 2006;107:1505-12.
12. Ciancio A, Picciotto A, Giordano C, Smedile A, Tabone M, Manca A, Marengo G, Garbagnoli P, Andreoni M, Cariti G, Calleri G, Sartori M, Cusumano S, Grasso A, Rizzi R, Gallo M, **Basso M**, Anselmo M, Percario G, Ciccone G, Rizzetto M, Saracco G. A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin. *Aliment Pharmacol Ther.* 2006;24:1079-86.
13. **Basso M**, Torre F, Grasso A, Percario G, Azzola E, Artioli S, Bianchi S, Pelli N, Picciotto A. Pegylated interferon and ribavirin in re-treatment of responder-relapser HCV patients. *Dig Liver Dis.* 2007;39:47-51.
14. De Maria A, Fogli M, Mazza S, **Basso M**, Picciotto A, Costa P, Congia S, Mingari MC, Moretta L. Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients. *Eur J Immunol.* 2007;37:445-55.
15. Pelli N, Floreani A, Torre F, Delfino A, Baragiotta A, Contini P, **Basso M**, Picciotto A. Soluble apoptosis molecules in primary biliary cirrhosis: analysis and commitment of the Fas and tumour necrosis factor-related apoptosis-inducing ligand systems in comparison with chronic hepatitis C. *Clin Exp Immunol.* 2007;148:85-9.
16. Zoppoli G, Di Maio G, Artioli S, Robaudo C, **Basso M**, Torre F, Cannella G, Picciotto A. Monotherapy with pegylated interferon alpha-2a in hemodialyzed patients with chronic hepatitis C. *Dialysis and Transplantation.*
17. Torre F, Bellis L, Delfino A, Pelli N, Contini P, **Basso M**, Puoti C, Picciotto A. Peripheral blood serum markers for apoptosis and liver fibrosis: are they trustworthy indicators of liver realness? *Dig Liver Dis.* 2008;40:441-5. 2008; 37:204-8.
18. **Basso M***, Giannini EG*, Torre F, Bianchi S, Savarino V, Picciotto A. Elevations in alanine aminotransferase levels late in the course of antiviral therapy in hepatitis C virus RNA-negative patients are associated with virological relapse. *Hepatology.* 2009;49:1442-8. * co-first
19. Giannini EG, Torre F, **Basso M**, Feasi M, Boni S, Grasso A, De Leo P, Dodi F, Marazzi MG, Azzola E, Bartolacci V, Percario G, Beltrame A, Borro P, Savarino V, Picciotto A; Ligurian Hepatitis B Virus Study Group. A significant proportion of patients with chronic hepatitis B who are candidates for antiviral treatment are untreated: A region-wide survey in Italy. *J Clin Gastroenterol.* 2009;43:1001-7.

20. Torre F, **Basso M**, Giannini EG, Feasi M, Boni S, Grasso A, De Leo P, Dodi F, Marazzi MG, Azzola E, Bartolacci V, Percario G, Beltrame A, Borro P, Picciotto A; Ligurian HBV Study Group. Clinical and virological survey of patients with hepatitis B surface antigen in an Italian region: clinical considerations and disease burden. *J Med Virol.* 2009 Nov;81(11):1882-6.
21. Giannini EG*, **Basso M***, Savarino V, Picciotto A. Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension. *J Intern Med.* 2009;266:537-46. * co-first
22. Giannini EG, **Basso M**, Bazzica M, Contini P, Marengo S, Savarino V, Picciotto A. Successful antiviral therapy determines a significant decrease in squamous cell carcinoma antigen-associated (SCCA) variants' serum levels in anti-HCV positive cirrhotic patients. *J Viral Hepat.* 2010;17:563-8.
23. Giannini EG*, **Basso M***, Savarino V, Picciotto A. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients. *Aliment Pharmacol Ther.* 2010;31:502-8. * co-first
24. Giannini EG, **Basso M**, Savarino V, Picciotto A. Predictive factors for response to peginterferon-alpha and ribavirin treatment of chronic HCV infection in patients aged 65 years and more. *Dig Dis Sci.* 2010;55:3193-9.
25. Torre F, Giannini EG, **Basso M**, Fazio V, Savarino V, Picciotto A. Initial high dose of lamivudine delays the appearance of viral resistance in chronic hepatitis B patients. *J Gastrointest Liver Dis.* 2011;20:47-50.
26. Parisi SG, Andreis S, Mengoli C, Scaggiante R, Ferretto R, Manfrin V, Cruciani M, Giobbia M, Boldrin C, **Basso M**, Andreoni M, Palù G, Sarmati L. Baseline cellular HIV DNA load predicts HIV DNA decline and residual HIV plasma levels during effective antiretroviral therapy. *J Clin Microbiol.* 2012;50:258-63.
27. Gramenzi A, Conti F, Cammà C, Grieco A, Picciotto A, Furlan C, Romagno D, Costa P, Rendina M, Ancarani F, Chiaramonte M, Verucchi G, Craxì A, Bernardi M, Andreone P; AISF HepaElder Study Group. Hepatitis C in the elderly: a multicentre cross-sectional study by the Italian Association for the Study of the Liver. *Dig Liver Dis.* 2012;44:674-80.
28. **Basso M**, Parisi SG, Mengoli C, Gentilini V, Menegotto N, Monticelli J, Nicolè S, Cruciani M, Palù G. Sustained virological response and baseline predictors in HIV-HCV coinfecting patients retreated with pegylated interferon and ribavirin after failing a previous interferon-based therapy: systematic review and meta-analysis. *HIV Clin Trials.* 2013;14:127-39.
29. Parisi SG, Andreis S, Mengoli C, Scaggiante R, Cruciani M, Ferretto R, Manfrin V, Panese S, **Basso M**, Boldrin C, Bressan S, Sarmati L, Andreoni M, Palù G. A stable CC-chemokine receptor (CCR)-5 tropic virus is correlated with the persistence of HIV RNA at less than 2.5 copies in successfully treated naïve subjects. *BMC Infect Dis.* 2013;13:314.
30. Parisi SG, Andreis S, Scaggiante R, Cruciani M, Ferretto R, Manfrin V, Panese S, Rossi MC, Francavilla E, Boldrin C, Dal Bello F, **Basso M**, Mengoli C, Andreoni M, Palù G. Decreasing trends of drug resistance and increase of non-B subtypes amongst subjects recently diagnosed as HIV-infected over the period 2004-2012 in the Veneto Region, Italy. *J Glob Antimicrob Resist.* 2013;1:201-206.
31. Strazzulla A, Costa C, Pisani V, De Maria V, Giancotti F, Di Salvo S, Parisi SG, **Basso M**, Franzetti MM, Marascio N, Liberto MC, Barreca GS, Lamberti AG, Zicca E, Postorino MC, Matera G, Focà A, Torti C. Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals. *BMC Infect Dis.* 2014;14 Suppl 5:S3.
32. Santantonio T, Fasano M, Sagnelli E, Tundo P, Babudieri S, Fabris P, Toti M, Di Perri G, Marino N, Pizzigallo E, Angarano G; Acute Hepatitis C Study Group. Acute hepatitis C: a 24-week course of pegylated interferon α -2b versus a 12-week course of pegylated interferon α -2b alone or with ribavirin. *Hepatology*2014;59:2101-9.
33. Wiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, Cullen KJ; EMCDDA DRID group, Hatzakis A, Prins M, Vickerman P, Lazarus JV, Hope VD, Matheï C. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. *PLoS One.* 2014 J;9:e103345.
34. **Basso M**, Franzetti M, Scaggiante R, Sattin A, Mengoli C, Cruciani M, Ficon M, Palù G, Parisi SG. HCV RNA viral load is independent from CD4 cell count and plasma HIV RNA viral load in immunocompetent HIV-HCV co-infected patients: a 3-years follow-up study. *AIDS Res Ther.* 2014;11:21.
35. Parisi SG, Sarmati L, Andreis S, Scaggiante R, Cruciani M, Ferretto R, Manfrin V, **Basso M**, Andreoni M, Mengoli C, Palù G. Strong and persistent correlation between baseline and follow-up HIV-DNA levels and residual viremia in a population of naïve patients with more than 4 years of effective antiretroviral therapy. *Clin Microbiol Infect.* 2015;21:288.e5-7.
36. Parisi SG, Bartolini A, Santacatterina E, Castellani E, Ghirardo R, Berto A, Franchin E, Menegotto N, De Canale E, Tommasini T, Rinaldi R, **Basso M**, Stefani S, Palù G. Prevalence of *Klebsiella pneumoniae* strains producing carbapenemases and increase of resistance to colistin in an Italian teaching hospital from January 2012 To December 2014. *BMC Infect Dis.* 2015 Jun 27;15:244.
37. Parisi SG, **Basso M**, Del Vecchio C, Andreis S, Franchin E, Dal Bello F, Pagni S, Biasolo MA, Manganelli R, Barzon L, Palù G. Viral infections of the central nervous system in elderly patients: a retrospective study. *Int J Infect Dis.* 2016;44:8-10.

38. Parisi SG, Basso M, Del Vecchio C, Andreis S, Franchin E, Bello FD, Pagni S, Biasolo MA, Manganelli R, Barzon L, Palù G. Virological testing of cerebrospinal fluid in children aged less than 14 years with a suspected central nervous system infection: A retrospective study on 304 consecutive children from January 2012 to May 2015. *Eur J Paediatr Neurol*. 2016;20:588-96.
39. Scaggiante R, Andreis S, **Basso M**, Franchin E, Franzetti M, Del Vecchio C, Torti C, Mengoli C, Cruciani M, Sarmati L, Palù G, Parisi SG. Epstein-Barr and cytomegalovirus DNA salivary shedding correlate with long-term plasma HIV RNA detection in HIV-infected men who have sex with men. *J Med Virol*. 2016;88:1211-21.
40. Parisi SG, Loregian A, Andreis S, Nannetti G, Cavinato S, **Basso M**, Scaggiante R, Dal Bello F, Messa L, Cattelan AM, Palù G. Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin. *Int J Infect Dis*. 2016;49:151-3.
41. Parisi SG, Basso M, Mengoli C, Scaggiante R, Andreis S, Franzetti MM, Cattelan AM, Zago D, Cruciani M, Andreoni M, Piovesan S, Palù G, Alberti A. Liver stiffness is not associated with short- and long-term plasma HIV RNA replication in immunocompetent patients with HIV infection and with HIV/HCV coinfection. *Ann Gastroenterol*. 2017;30:534-541.
42. Mengoli C, Andreis S, Scaggiante R, Cruciani M, Bosco O, Ferretto R, Leoni D, Maffongelli G, **Basso M**, Torti C, Sarmati L, Andreoni M, Palù G, Parisi SG. Structural equation modelling of viral tropism reveals its impact on achieving viral suppression within 6 months in treatment-naïve HIV-1-infected patients after combination antiretroviral therapy. *J Antimicrob Chemother*. 2017 ;72:220-226.
43. Nannetti G, Messa L, Celegato M, Pagni S, **Basso M**, Parisi SG, Palù G, Loregian A. Development and validation of a simple and robust HPLC method with UV detection for quantification of the hepatitis C virus inhibitor daclatasvir in human plasma. *J Pharm Biomed Anal*. 2017;134:275-281.
44. Bartolini A, **Basso M**, Franchin E, Menegotto N, Ferrari A, De Canale E, Andreis S, Scaggiante R, Stefani S, Palù G, Parisi SG. Prevalence, molecular epidemiology and intra-hospital acquisition of *Klebsiella pneumoniae* strains producing carbapenemases in an Italian teaching hospital from January 2015 to September 2016. *Int J Infect Dis*. 2017;59:103-109.
45. Andreis S*, **Basso M***, Scaggiante R, Cruciani M, Ferretto R, Manfrin V, Panese S, Rossi MC, Francavilla E, Boldrin C, Alvarez M, Dal Bello F, Mengoli C, Turriziani O, Sarmati L, Antonelli G, Andreoni M, Palù G, Parisi SG. Drug resistance in B and non-B subtypes amongst subjects recently diagnosed as primary/recent or chronic HIV-infected over the period 2013-2016: Impact on susceptibility to first-line strategies including integrase strand-transfer inhibitors. *J Glob Antimicrob Resist*. 2017;10:106-112. *co-first
46. Parisi SG, Andreis S, **Basso M**, Cavinato S, Scaggiante R, Franzetti M, Andreoni M, Palù G, Cattelan AM. Time course of cellular HIV-DNA and low-level HIV viremia in HIV-HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals. *Med Microbiol Immunol*. 2017;206:419-428.
47. Parisi SG, Andreis S, Mengoli C, Menegotto N, Cavinato S, Scaggiante R, Andreoni M, Palù G, **Basso M***, Cattelan AM*. Soluble CD163 and soluble CD14 plasma levels but not cellular HIV-DNA decrease during successful interferon-free anti-HCV therapy in HIV-1-HCV co-infected patients on effective combined anti-HIV treatment. *Med Microbiol Immunol*. 2018;207:183-194. * co-last
48. **Basso M***, Andreis S*, Scaggiante R, Franchin E, Zago D, Biasolo MA, Del Vecchio C, Mengoli C, Sarmati L, Andreoni M, Palù G, Parisi SG. Cytomegalovirus, Epstein-Barr virus and human herpesvirus 8 salivary shedding in HIV positive men who have sex with men with controlled and uncontrolled plasma HIV viremia: a 24-month longitudinal study. *BMC Infect Dis*. 2018 ;18:683. * co-first
49. **Basso M***, Venditti C*, Raponi G, Navazio AS, Alessandri F, Giombini E, Nisii C, Di Caro A, Venditti M. A case of persistent bacteraemia by *Ralstonia mannitolilytica* and *Ralstonia pickettii* in an intensive care unit. *Infect Drug Resist*. 2019;12:2391-2395. *co-first
50. Mengoli C*, **Basso M***, Andreis S, Scaggiante R, Cruciani M, Ferretto R, Panese S, Manfrin V, Francisci D, Schiaroli E, Maffongelli G, Sarmati L, Andreoni M, Baldelli F, Palu' G, Parisi SG. Role of pretreatment variables on plasma HIV RNA value at the sixth month of antiretroviral therapy including all first line drugs in HIV naïve patients: A path analysis approach. *PLoS One*. 2019;14:e0213160. *co-first
51. Parisi SG, **Basso M**, Scaggiante R, Andreis S, Mengoli C, Cruciani M, Del Vecchio C, Menegotto N, Zago D, Sarmati L, Andreoni M, Palù G. Oral and anal high-risk human papilloma virus infection in HIV-positive men who have sex with men over a 24-month longitudinal study: complexity and vaccine implications. *BMC Public Health*. 2019;19:645.
52. McDermott J, Parisi SG, Martini I, Boldrin C, Franchin E, Dal Bello F, Gianelli Castiglione A, Boeri E, Sampaolo M, **Basso M**, Menegazzi P, Tagliaferro L, Palù G, Varnier OE. Detection of hepatitis C virus in an exhumed body identified the origin of a nosocomial transmission that caused multiple fatal diseases. *J Hosp Infect*. 2019;102:332-336.
53. **Basso M***, Zago D*, Pozzetto I, De Canale E, Scaggiante R, Biasolo MA, Peracchi M, Onelia F, Baldasso E, Palù G, Parisi SG. Intra-hospital acquisition of colonization and infection by *Klebsiella pneumoniae* strains producing carbapenemases and carriage evolution: A longitudinal analysis in an Italian teaching hospital from January 2017 to August 2019. *Int J Infect Dis*. 2020 ;92:81-88. * co-first

54. **Basso M**, Zago D, Pozzetto I, Del Vecchio C, Franchin E, Dal Bello F, Pagni S, Maria, AB., Manganelli, R., Palù, G., Parisi, S.G. Viral molecular testing of cerebrospinal fluid in adults with suspected central nervous system infection in an Italian university hospital laboratory: A retrospective study on 1462 consecutive patients. *Open Microbiol. J.* 2021; 15: 26-35.
55. Malagnino V, Teti E, Compagno M, Coppola L, Salpini R, Svicher V, **Basso M**, Battagin G, Panese S, Rossi MC, Scaggiante R, Zago D, Iannetta M, Parisi SG, Andreoni M, Sarmati L. HBcAb Positivity Is a Risk Factor for an Increased Detectability of HIV RNA after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Analysis of a Multicenter Italian Cohort. *Microorganisms.* 2021;9:396.
56. **Basso M**, Zago D, Pozzetto I, Battagin G, Carlotto A, Rossi MC, Panese S, Sarmati L, Parisi SG. Sustained virological response after treatment with direct-acting antivirals can help immune reconstitution in HIV-HCV coinfecting patients even in case of persistent HIV low-level viremia. *Health Sci Rep.* 2020;4:e221.
57. Vicenti I, Gatti F, Scaggiante R, Boccuto A, Modolo E, Zago D, **Basso M**, Dragoni F, Bartolini N, Zazzi M, Parisi SG. Time Course of Neutralizing Antibody in Health Care Workers With Mild or Asymptomatic COVID-19 Infection. *Open Forum Infect Dis.* 2021 ;8:ofab312.
58. Vicenti I, Gatti F, Scaggiante R, Boccuto A, Zago D, **Basso M**, Dragoni F, Zazzi M, Parisi SG. Single-dose BNT162b2 mRNA COVID-19 vaccine significantly boosts neutralizing antibody response in health care workers recovering from asymptomatic or mild natural SARS-CoV-2 infection. *Int J Infect Dis.* 2021 ;108:176-178.
59. Vicenti I, Gatti F, Scaggiante R, Boccuto A, Zago D, **Basso M**, Dragoni F, Parisi SG, Zazzi M. BNT162b2 SARS-CoV-2 Vaccination Elicits High Titers of Neutralizing Antibodies to Both B.1 and P.1 Variants in Previously Infected and Uninfected Subjects. *Life (Basel).* 2021;11:896.
60. Vicenti I, **Basso M**, Gatti F, Scaggiante R, Boccuto A, Zago D, Modolo E, Dragoni F, Parisi SG, Zazzi M. Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose. *Int J Infect Dis.* 2021;112:40-44.
61. **Basso M**, Zago D, Pozzetto I, Parisi SG. Hepatitis C virus viral load distribution in the era of extended access to direct acting antivirals treatment: a real-life single center study. *Eur J Gastroenterol Hepatol.* 2021;33(1S Suppl 1):e1076-e1077.
62. **Basso M**, Zago D, Scaggiante R, Cavinato S, Pozzetto I, Stagni C, Parisatto B, Cattelan AM, Battagin G, Sarmati L, Parisi SG. HIV tropism switch in archived DNA of HIV-HCV subjects successfully treated with direct-acting antivirals for HCV infection. *Sci Rep.* 2021;11:9274.
63. Zago D, Pozzetto I, Pacenti M, Brancaccio G, Ragolia S, **Basso M***, Parisi SG*. Circulating Genotypes of Hepatitis C Virus in Italian Patients before and after the Application of Wider Access Criteria to HCV Treatment. *Open Microbiol. J.* 2022, 16, e187428582205300. * co-last
64. Vicenti I, **Basso M**, Dragoni F, Gatti F, Scaggiante R, Fiaschi L, Parisi SG, Zazzi M. Comparable Post-Vaccination Decay of Neutralizing Antibody Response to Wild-Type and Delta SARS-CoV-2 Variant in Healthcare Workers Recovered from Mild or Asymptomatic Infection. *Vaccines (Basel).* 2022;10:580.
65. Vicenti I, Gatti F, Scaggiante R, Boccuto A, Zago D, **Basso M**, Dragoni F, Parisi SG, Zazzi M. The second dose of the BNT162b2 mRNA vaccine does not boost SARS-CoV-2 neutralizing antibody response in previously infected subjects. *Infection.* 2022; 50: 541-543
66. Parisi SG, Mengoli C, **Basso M**, Vicenti I, Gatti F, Scaggiante R, Fiaschi L, Giammarino F, Iannetta M, Malagnino V, Zago D, Dragoni F, Zazzi M. Long-Term Longitudinal Analysis of Neutralizing Antibody Response to Three Vaccine Doses in a Real-Life Setting of Previously SARS-CoV-2 Infected Healthcare Workers: A Model for Predicting Response to Further Vaccine Doses. *Vaccines (Basel).* 2022;10:1237.
67. **Basso M**, Pirola N, Pascoli S, Bragato B, Vinci A, Iannetta M, Colombo F, Geremia N, Martignago L, Rossi MC, Cipriani L, Giobbia M, Scotton PG, Parisi SG. Humoral Response after Two Doses of BNT162b2 mRNA Vaccine Has a Role in Predicting Response after Three Doses That Is Related to Plasma HIV Viremia and Nadir CD4+ Cell Count in HIV-Positive Patients. *Vaccines (Basel).* 2022;11:82.
68. Malagnino V, Salpini R, Teti E, Compagno M, Ferrari L, Mulas T, Svicher V, Zordan M, **Basso M**, Battagin G, Panese S, Rossi MC, Scaggiante R, Zago D, Iannetta M, Parisi SG, Andreoni M, Sarmati L. Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort. *Viruses.* 2023;15:193.
69. Vicenti I*, **Basso M***, Pirola N, Bragato B, Rossi MC, Giobbia M, Pascoli S, Vinci A, Caputo S, Varasi I, Biba C, Fiaschi L, Zazzi M, Parisi SG. SARS-CoV-2 Neutralizing Antibodies to B.1 and to BA.5 Variant after Booster Dose of BNT162b2 Vaccine in HIV Patients COVID-Naïve and on Successful Antiretroviral Therapy. *Vaccines (Basel).* 2023;11:871. * co-first
70. Bergantini L, Baldassarri M, d'Alessandro M, Brunelli G, Fabbri G, Zguro K, Degl'Innocenti A; GEN-COVID Multicenter study; Fallerini C, Bargagli E, Renieri A. Ultra-rare RTEL1 gene variants associate with acute severity of COVID-19 and evolution to pulmonary fibrosis as a specific long COVID disorder. *Respir Res.* 2023;24:158. M Basso aderisce al GEN-COVID Multicenter study.
71. **Basso M**, Battagin G, Nicolè S, Rossi MC, Colombo F, Pirola N, Baratti S, Storato S, Giovagnorio F, Malagnino V, Alessio G, Vinci A, Maurici M, Sarmati L, Parisi SG. Predicting Factors of Plasma HIV RNA Undetectability

after Switching to Co-Formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Experienced HIV-1 Patients: A Multicenter Study. Viruses. 2023;15:1727.

La sottoscritta è a conoscenza che, ai sensi dell'art 76 del DPR 445/2000, le dichiarazioni mendaci la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali.

Padova, 29 gennaio 2024

Monica Basso

